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Abstract. NINEIN serves an essential role in centrosome 
function as a microtubule organizing center, and in the refor‑
mation of the interphase centrosome architecture following 
mitosis. In the present study, the association between NINEIN 
Pro1111Ala (rs2236316), a missense single nucleotide poly‑
morphism, and the risk of colorectal cancer (CRC), related to 
smoking and alcohol consumption habits in 200 patients with 
CRC and 1,141 cancer‑free control participants were assessed 
in a case‑control study performed in Japan. The results showed 
that the NINEIN Ala/Ala genotype compared with the Pro/Pro 
genotype was significantly more associated with an increased 
risk of CRC, and the males with the Ala/Ala genotype exhib‑
ited a significantly increased risk of CRC compared with those 
with Pro/Pro and Pro/Ala genotypes. Stratified analyses of the 
Ala/Ala genotype with CRC risk further showed an increased 
association in never/light drinkers (<23 g of ethanol/day), in 
male never/light drinkers and in male patients with rectal 
cancer. These findings suggest that the genetic variant of the 
NINEIN Pro1111Ala polymorphism has a significant effect on 
CRC susceptibility in the Japanese population.
Introduction
Colorectal cancer (CRC) is a common malignancy with high 
incidence and mortality rates both in male and female patients 
in Japan, although the overall 5‑year survival rate is relatively 
high (95.5, 88.5 and 76.5% for patients with stages I, II and 
III CRC, respectively) (1). At present, the implementation of 
CRC population screening has contributed to the reduction of 
morbidity and mortality rates, which indicates that the earlier 
the CRC diagnosis is confirmed, the more effective and easier 
the therapeutic treatment to patients will be, resulting in favor‑
able prognoses. Among the different epidemiological factors, 
cigarette smoking and alcohol consumption have been known 
to be associated with a higher risk of CRC (2‑6). In particular, 
alcohol consumption shows a significantly higher association 
with CRC in Japanese individuals compared with Western 
populations (7).
CRC tumor location has been hypothesized to have impor‑
tant implications in clinical and pathological aspects. The 
left side of the colon, consisting of the descending colon, the 
sigmoid colon and the rectum, has a different embryonic origin 
than the right side of colon, which consists of the cecum, the 
ascending colon and the transverse colon (8,9). Therefore, the 
two sides of the colon have discrete physiological characteris‑
tics and molecular backgrounds. Recent advances in molecular 
biology have revealed that CRC is classified into two, mutu‑
ally exclusive, distinct types based on the genomic instability. 
Microsatellite instability (MIN) occurs in the proximal 
segments (right colon), and chromosomal instability (CIN) 
arises in the distal segments (left colon and the rectum) of the 
large bowel, respectively (8,9). The proximal and distal regions 
have different and distinct embryological origins, which subse‑
quently show different anatomical and functional structures 
and properties, respectively (8). The CIN pathway is considered 
the traditional colon cancer progression pathway, in which the 
molecular model of the Vogelstein's adenoma‑to‑carcinoma 
sequence, characterized by a progressive accumulation of 
genetic alterations, such as mutations in KRAS, APC, DCC, 
TP53 with a loss of heterozygosity, and global hypometh‑
ylation is relevant (10). MIN is another mutator pathway, 
characterized by the dysfunctional mismatch repair genes and 
a secondary mutation of the genes with coding microsatellites 
through the methylation of promoters (9,10). The expression 
of cancer‑associated genes may be altered either by aberrant 
DNA hypomethylation of global DNA, typically observed 
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in the CIN pathway, or by hypermethylation of promoters, 
observed in the MIN pathway (10). Furthermore, dysregula‑
tion of centrosome function or chromosomal segregation may 
predispose patients to CIN‑related cancer development (11).
NINEIN is a centrosomal protein, identified as the microtu‑
bules' minus‑end capping, centriole position and an anchoring 
protein. NINEIN serves essential roles in the formation of the 
mitotic spindle, cell polarity and cell locomotion (12‑16). It 
contains an N‑terminal potential GTPase/GTP‑binding site, a 
large coiled‑coil domain with four leucine zippers, C‑terminal 
oligomerization and a GSK3β‑binding domain (14,17). 
The significance of the NINEIN coiled‑coil II domain, 
co‑localizing with γ‑tubulin and centrin at the centrosome, 
is associated with a centrosomal targeting signal, regulating 
signal and phosphorylation sites (13). NINEIN has been 
suggested to contribute to the complex centrosome architec‑
ture and regulate centrosome asymmetry for controlling cell 
polarity during the cell cycle (13). Although some missense 
mutations and allelic variants in the NINEIN gene are report‑
edly associated with microcephalic primordial dwarfism 
disorder, a phenotype associated with a severe form of human 
growth failure and shared by the Seckel syndrome (18,19), or 
spondyloepimetaphyseal dysplasia (20), their association with 
CRC remains to be clarified.
A number of single nucleotide polymorphism in genes 
controlling centrosome function has been shown to be asso‑
ciated with an increased risk of developing and promoting a 
range of different types of cancer (21,22); however, the value of 
single nucleotide polymorphisms of the NINEIN gene have not 
been assessed yet, to the best of our knowledge. In the present 
study, the effects of the NINEIN Pro1111Ala (rs2236316) poly‑
morphism on the risk of CRC and its association with cigarette 
smoking, alcohol consumption and tumor position of CRC in 
the Japanese population were assessed.
Materials and methods
Study population. The cases of 200 Japanese patients with 
primary CRC whose tumors were operated on and histologi‑
cally confirmed at Okayama University Hospital (Okayama, 
Japan) between 1994‑2005 (specific months unavailable) were 
retrospectively analyzed. The clinical and histopathological 
classification of the tumors was performed according to 
the criteria of the Union for International Cancer Control 
Tumor‑Node‑Metastasis Classification of Malignant Tumors, 
6th edition, 2002 (23). There were two hereditary CRC cases 
(one case of hereditary non‑polyposis CRC and one case of 
familial adenomatous polyposis), and one case of ulcerative 
colitis‑associated with CRC, all of which were also included 
in the analysis. For the controls, 1,141 Japanese patients 
consisting of two groups: 227 Outpatients without cancer who 
visited Kusaka Hospital at Okayama in 2005, and 914 healthy 
individuals who visited Junpukai Health Care Center at 
Okayama for medical check‑up in 2009. The median age of 
the 200 Japanese patients with colorectal cancer was 64 years 
(age range, 23‑89 years), and consisted of 115 males and 
85 females. The median age of 1,141 individuals in the control 
group was 55 years (age range, 32‑94 years), and consisted 
of 675 males and 466 females. The median age of all study 
participants was 56 (age range, 23‑94).
The age, sex, personal and family medical histories, and 
smoking and drinking history of the subjects were obtained 
from interviews and medical questionnaire records. The 
smoking status was assessed by pack‑year equivalents 
[(cigarettes per day/20)x(smoking years)]. The classifica‑
tion of smoking status for the present study was as follows: 
Never/light smokers (<20 pack‑years), or heavy smokers 
(≥20 pack‑years). Alcohol consumption status was assessed as 
the daily ethanol intake calculated as follows: One serving of 
sake contains ~23 g ethanol, which is roughly the equivalent 
of two U.S. standard drinks, where one U.S. drink contains 
14 g ethanol (7). The recommended daily maximum amount 
of alcohol was based on the report regarding the limitation on 
daily ethanol intake issued by the Ministry of Health, Labor 
and Welfare (20 g/day; Healthy Japan 21, a national healthcare 
movement). According to the prospective large cohort study 
showing the lowest all‑cause mortality including cancer in both 
Japanese men and women with ethanol intake <23 g/day (7), 
the subjects were classified as non/light drinkers (<23 g/day), 
or heavy drinkers (<23 g/day).
All patients and controls provided written informed consent 
to participate in the present study prior to the start of the study, 
and the Bioethics Committee of Okayama University Medical 
School (Okayama, Japan) approved the present study.
Genotype analysis. Genomic DNA was extracted from 
peripheral blood lymphocytes or freshly frozen non‑neoplastic 
colorectal mucosae according to standard procedures using 
proteinase K and phenol‑chloroform (24). The genotyping of 
the polymorphisms including NINEIN Pro1111Ala (rs2236316) 
was performed using SNaPshot kit (Applied Biosystems; 
Thermo Fisher Scientific, Inc.) according to the manufacture's 
instruction. Briefly, the target region for genotyping was ampli‑
fied by PCR, with a final reaction volume of 10 µl containing 
10 ng template DNA, 1.0 pmol of each primer, 2.0 mM dNTPs, 
1 µl 10x PCR buffer and 0.25 units Taq DNA polymerase 
(Takara Bio, Inc.). The thermocycling conditions were: Initial 
denaturation at 94˚C for 3 min; followed by 32 cycles at 94˚C 
for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec; and a final 
extension step of 72˚C for 7 min. PCR products were treated 
with 2.0 units exonuclease I and 0.5 units shrimp alkaline 
phosphatase to remove unreacted primers and dNTPs by 
incubating at 37˚C for 90 min and at 75˚C for 15 min. The 
first PCR primer set sequences were: Sense 5'‑GGA AAA TGT 
GAA AAT GGC TAC TGA‑3' and anti‑sense 5'‑GAC TCC TCT 
ATT TTG ACT TCC TGT‑3'.
Subsequently, a single nucleotide primer extension reac‑
tion was performed using SNaPshot kit with a final reaction 
volume of 10 µl, containing 3 µl purified PCR products, 
20 mM (NH4)2SO4 and 2 µl SNaPshot Ready Reaction mix 
containing fluorescently labeled ddNTPs and DNA poly‑
merase. The sequence of the genotyping primer for NINEIN 
Pro1111Ala was 5'‑TTT TTT TTT TTT TTT TTT TTT TTT 
TTG TTA GTA ATG TCT TCT TGT TTG GAT GAG‑3'. The 
thermocycling conditions were: Initial denaturation at 96˚C 
for 3 min; followed by 30 cycles at 96˚C for 10 sec, 50˚C 
for 5 sec and 60˚C for 30 sec. To remove unincorporated 
ddNTPs, the reaction was incubated with 1.0 unit shrimp 
alkaline phosphatase at 37˚C for 90 min and at 75˚C for 
15 min and then 8.5 µl HI‑Di formamide, 0.5 µl Genescan 
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120 LIZ size standard (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) and 1 µl reaction mixture were combined and 
denatured at 95˚C for 5 min and incubated at 4˚C for 2 min. 
The products were electrophoresed using an ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) and analyzed using GeneMapper version 3.0 
Software SNaPshot Analysis (Applied Biosystems; Thermo 
Fisher Scientific, Inc.).
Human genetic variation database (HGVD) is a publicly 
available database of known genetic variations in 1,208 
Japanese individuals, and was used as an additional represen‑
tative of healthy controls to confirm the validity of genotype 
distributions in the control group (25). According to data‑
bases instructions, the genotype count of objective the single 
nucleotide polymorphism, rs2236316 was obtained.
Human Protein Atlas Database analysis. Protein expression 
of NINEIN in colorectal cancer patient tissues and its correla‑
tion with prognosis was examined by using Human Protein 
Atlas Database (proteinatlas.org/).
Statistical analysis. All analyses were performed using SPSS 
version 24 (IBM Corp.). Allele frequency was calculated by 
direct counting. Deviation of the genotype frequency from the 
Hardy‑Weinberg equilibrium was analyzed using Pearson's 
χ2 test. The distribution of genotype frequencies between 
cancer cases and controls were analyzed using a χ2 test. The 
risk of CRC was estimated using odds ratio (ORs) and 95% 
confidence interval (CIs). Analyses were adjusted for sex, age, 
smoking status and alcohol consumption status using a multi‑
variate logistic regression model by comparing the genotypes 
between the cases and controls. P<0.05 was considered to 
indicate a statistically significant difference.
Results
Association of the NINEIN Pro1111Ala polymorphism 
with CRC risk. The demographics and clinicopathological 
characteristics of the patients with CRC and controls are 
presented in Table I. There was no difference in sex distribu‑
tion between the patients with CRC and controls, whereas 
patients with CRC had a higher median age, consumed more 
alcohol and smoked more. Genotype analysis of NINEIN 
Pro1111Ala polymorphism (rs2236316) in the patients with 
CRC and controls are summarized in Table II. The Ala/Ala 
genotype was significantly associated with the risk of CRC 
compared with the Pro/Pro genotype (OR=2.09, 95% CI 
1.12‑3.91, P=0.02), whereas allele frequency differences 
[Pro‑allele/Ala‑allele: 307/93 (76.8%/23.3%) for cases and 
1815/467 (79.5%/20.5%) for controls] were not associated 
with a risk of CRC (P=0.21).
Among males, the Ala/Ala genotype was more significantly 
associated with an increased risk of CRC in the recessive 
genetic model compared with the Pro/Pro and Pro/Ala geno‑
types (OR=2.76, 95% CI 1.27‑6.04, P=0.01). There was no 
association between the genotypes and the risk of CRC among 
females (Table III).
The genotype frequency of rs2236316 in the control group 
was in Hardy‑Weinberg equilibrium, both in the entire cohort, 
and in the patients obtained from each institution (data not 
shown). The genotype frequency of rs2236316 in the control 
group was similar to that of HGVD, which consisted of 1,208 
Japanese individuals, suggesting that the sample used in the 
present study was representative of the general Japanese popu‑
lation (25). In HGVD, the rs2236316 genotype distribution was 
748 (62%), 412 (34%) and 43 (4%) for Pro/Pro, Pro/Ala and 
Ala/Ala, respectively.
Association of the NINEIN genotype with smoking and 
alcohol consumption. Subsequently, the association between 
smoking or alcohol consumption, NINEIN Pro1111Ala geno‑
types and the risk of CRC were assessed in the stratified 
analyses (Table IV). Among the never/light drinkers (<23 g of 
ethanol/day), there was a significant association of the Ala/Ala 
genotype with an increased risk of CRC compared with the 
Pro/Pro and Pro/Ala genotype in the recessive genetic model 
(OR=2.59, 95% CI 1.31‑5.12, P=0.006). There was no signifi‑
cant association among smokers in the stratified analysis. As 
the Ala/Ala genotype showed a significantly increased risk 
of CRC only in males, a stratified analysis of smoking and 
alcohol consumption among males was performed. The results 
are summarized in Table V. Only the group of the never/light 
drinkers with the Ala/Ala genotype exhibited a significant 
association with CRC risk in the recessive model compared 
with the Pro/Pro and Pro/Ala genotypes (OR=4.90, 95% CI 
1.91‑12.58, P=0.001).
Association of the NINEIN genotype with cancer locations. 
The association between the NINEIN genotypes and cancer 
locations among male patients were analyzed, as the left and 
right colon have different embryologic origins, and are thus 
subject to different epigenetic backgrounds (8,10). Separately 
Table I. Characteristics of patients with CRC and the healthy 
controls.
 CRC  Controls,
Characteristics patients, n (%) n (%) P‑value
Total 200 (100) 1,141 (100) 0.66
  Males  115 (57.5)     675 (59.2)
  Females    85 (42.5)     466 (40.8)
Age, years   <0.001b
  <50 18 (9)     255 (22.3)
  50‑59    57 (28.5)     501 (43.9)
  60‑69 58 (29)     261 (22.9)
  ≥70    67 (33.5)     124 (10.9)
  Median 64 55
  Range 23‑89 32‑94
Smoking   0.01a
  Never/light smokers 119 (59.5)     782 (68.5)
  Heavy smokers   81 (40.5)     359 (31.5)
Alcohol consumption   <0.001b
  Never/light drinkers 137 (68.5)     906 (79.4)
  Heavy drinkers   63 (31.5)     235 (20.6)
aP<0.05, bP<0.001. CRC, colorectal cancer.
YASUDA et al:  HUMAN NINEIN POLYMORPHISM IN COLON CANCER4
analyzing the left side of the colon (the descending colon, the 
sigmoid colon and the rectum), and the right side of the colon 
(the cecum, the ascending colon and the transverse colon), 
only the left colon‑group exhibited increased risk if they had 
an Ala/Ala genotype compared with the Pro/Pro and Pro/Ala 
genotypes in the recessive model (OR=2.42, 95% CI 1.01‑5.82, 
P=0.049; Table VI). Further comparisons between colon 
cancer and rectal cancer (left‑sided) patients, showed that only 
rectal cancer cases indicated a significant association with 
an Ala/Ala genotype (OR=3.30, 95% CI 1.26‑8.61, P=0.01), 
whereas such an association was not observed in cancer of any 
other regions (Table VI), nor in the total patients and female 
patients (data not shown).
Stratification of the association of the NINEIN genotype with 
a combination of smoking or alcohol consumption status and 
the location of CRC in males. The stratified analysis of the 
combined effects of cancer locations and smoking or alcohol 
consumption history among males are shown in Table VII. In 
this table analyses without significant adjusted odds ratio (aOR) 
were omitted. For smoking, male heavy smokers showed an 
aOR of 6.94 (P=0.03) with right colon cancer, and male light 
smokers showed an aOR of 8.83 (P=0.01) among rectal cancer. 
However, the range of their CIs were notably wide in both 
cases, 1.18‑40.82 for the former and 1.92‑40.56 for the latter, 
suggesting a comparably low reliability. For alcohol consump‑
tion, showing multiple significant ORs in the stratified light 
Table II. Association between NINEIN Pro1111Ala (rs2236316) genotype and risk of CRC.
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 200 (100) 1,141 (100)
Pro/Proc 124 (62) 720 (63.1)
Pro/Ala 59 (29.5) 375 (32.9) 0.99 (0.70‑1.39) 0.94
Ala/Ala 17 (8.5) 46 (4) 2.09 (1.12‑3.91) 0.02a
Pro/Ala+Ala/Ala 76 (38) 421 (36.9) 1.11 (0.81‑1.54) 0.51
Pro/Pro+Pro/Alac 183 (91.5) 1,095 (96)
Ala/Ala 17 (8.5) 46 (4) 2.1 (1.14‑3.89) 0.02a
aP<0.05. bAdjusted for sex, age, smoking, and alcohol consumption. cUsed as reference. CRC, colorectal cancer.
Table III. Association between NINEIN genotype and sex in patients with CRC.
A, Males    
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 115 (100) 675 (100)
Pro/Proc 74 (64.3) 422 (62.5)
Pro/Ala 30 (26.1) 228 (33.8) 0.85 (0.53‑1.36) 0.5
Ala/Ala 11 (9.6) 25 (3.7) 2.63 (1.19‑5.81) 0.02a
Pro/Ala+Ala/Ala 41 (35.7) 253 (37.5) 1.04 (0.67‑1.59) 0.87
Pro/Pro+Pro/Alac 104 (90.4) 650 (96.3)
Ala/Ala 11 (9.6) 25 (3.7) 2.76 (1.27‑6.04) 0.01a
B, Females
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 85 (100) 466 (100)
Pro/Proc 50 (58.8) 298 (63.9)
Pro/Ala 29 (34.1) 147 (31.5) 1.21 (0.72‑2.04) 0.47
Ala/Ala 6 (7.1) 21 (4.5) 1.5 (0.54‑4.17) 0.44
Pro/Ala+Ala/Ala 35 (41.2) 168 (36.1) 1.25 (0.76‑2.05) 0.37
Pro/Pro+Pro/Alac 79 (92.9) 445 (95.5)
Ala/Ala 6 (7.1) 21 (4.5) 1.4 (0.51‑3.84) 0.51
aP<0.05. bAdjusted for sex, age, smoking, and alcohol consumption. cUsed as reference. CRC, colorectal cancer.
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drinkers, the effects of light drinking on the risk of the Ala/Ala 
genotype are presented above. Overall, light drinkers showed 
an aOR of 2.65 (P=0.01), higher than that of the non‑stratified 
overall aOR of 2.09 (P=0.02; Table IV). Male‑only light 
drinkers showed an aOR of 4.83 (P=0.001) (Table V); 9.51 
(P=0.003) for right colon cancer; and 3.73 (P=0.02) for left 
colon cancer (Table VII). Male light drinkers were further 
stratified into rectal cancer and colon (other than rectal) cancer, 
Table IV. Association between NINEIN genotype and smoking or alcohol consumption in patients with CRC.
A, Never/light smokers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 119 (100) 782 (100)
Pro/Proc 71 (59.7) 492 (62.9)
Pro/Ala 38 (31.9) 257 (32.9) 1.04 (0.67‑1.6) 0.86
Ala/Ala 10 (8.4) 33 (4.2) 1.97 (0.89‑4.33) 0.09
Pro/Ala+Ala/Ala 48 (40.3) 290 (37.1) 1.15 (0.77‑1.72) 0.5
Pro/Pro+Pro/Alac 109 (91.6) 749 (95.8)
Ala/Ala 10 (8.4) 33 (4.2) 1.94 (0.89‑4.21) 0.09
B, Heavy smokers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 81 (100) 359 (100)
Pro/Proc 53 (65.4) 228 (63.5)
Pro/Ala 21 (25.9) 118 (32.9) 0.99 (0.55‑1.78) 0.97
Ala/Ala 7 (8.6) 13 (3.6) 2.38 (0.84‑6.71) 0.1
Pro/Ala+Ala/Ala 28 (34.6) 131 (36.5) 1.16 (0.67‑1.98) 0.6
Pro/Pro+Pro/Alac 74 (91.4) 346 (96.4)
Ala/Ala 7 (8.6) 13 (3.6) 2.39 (0.86‑6.63) 0.09
C, Never/light drinkers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 137 (100) 906 (100)
Pro/Proc 80 (58.4) 572 (63.1)
Pro/Ala 43 (31.4) 298 (32.9) 1.08 (0.72‑1.62) 0.72
Ala/Ala 14 (10.2) 36 (4) 2.65 (1.32‑5.33) 0.01a
Pro/Ala+Ala/Ala 57 (41.6) 334 (36.9) 1.26 (0.86‑1.83) 0.24
Pro/Pro+Pro/Alac 123 (89.8) 870 (96)
Ala/Ala 14 (10.2) 36 (4) 2.59 (1.31‑5.12) 0.01a
D, Heavy drinkers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 63 (100) 235 (100)
Pro/Proc 44 (69.8) 148 (63)
Pro/Ala 16 (25.4) 77 (32.8) 0.84 (0.43‑1.64) 0.61
Ala/Ala 3 (4.8) 10 (4.3) 1.00 (0.24‑4.08) 1
Pro/Ala+Ala/Ala 19 (30.2) 87 (37) 0.86 (0.46‑1.62) 0.64
Pro/Pro+Pro/Alac 60 (95.2) 225 (95.7)
Ala/Ala 3 (4.8) 10 (4.3) 1.05 (0.26‑4.25) 0.95
aP<0.05. bAdjusted for sex, age, smoking, and alcohol consumption. cUsed as reference. CRC, colorectal cancer.
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and a significant aOR was observed only in male patients with 
rectal cancer; the colon (other than rectal) cancer also showed 
an almost significant result (aOR=3.92, P=0.0501; Table VII).
Association of the NINEIN protein expression with CRC prog-
nosis. Alteration of NINEIN at the genomic and transcriptional 
levels remains to be investigated in the CRC. The Human Protein 
Table V. Association between NINEIN genotype and smoking or alcohol consumption in male patients with CRC.
A, Never/light smokers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 39 (100) 336 (100)
Pro/Proc 24 (61.5) 207 (61.6)
Pro/Ala 11 (28.2) 117 (34.8) 0.8 (0.38‑1.69) 0.56
Ala/Ala 4 (10.3) 12 (3.6) 2.99 (0.88‑10.14) 0.08
Pro/Ala+Ala/Ala 15 (38.5) 129 (38.4) 0.99 (0.50‑1.97) 0.98
Pro/Pro+Pro/Alac 35 (89.7) 324 (96.4)
Ala/Ala 4 (10.3) 12 (3.6) 3.23 (0.98‑10.69) 0.055
B, Heavy smokers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 76 (100) 339 (100)
Pro/Proc 50 (65.8) 215 (63.4)
Pro/Ala 19 (25) 111 (32.7) 0.99 (0.54‑1.83) 0.98
Ala/Ala 7 (9.2) 13 (3.8) 2.39 (0.84‑6.80) 0.1
Pro/Ala+Ala/Ala 26 (34.2) 124 (36.6) 1.17 (0.67‑2.06) 0.58
Pro/Pro+Pro/Alac 69 (90.8) 326 (96.2)
Ala/Ala 7 (9.2) 13 (3.8) 2.4 (0.86‑6.71) 0.09
C, Never/light drinkers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 57 (100) 456 (100)
Pro/Proc 33 (57.9) 286 (62.7)
Pro/Ala 16 (28.1) 155 (34) 0.96 (0.50‑1.81) 0.89
Ala/Ala 8 (14) 15 (3.3) 4.83 (1.84‑12.69) 0.001a
Pro/Ala+Ala/Ala 24 (42.1) 170 (37.3) 1.3 (0.74‑2.31) 0.36
Pro/Pro+Pro/Alac 49 (86) 441 (96.7)
Ala/Ala 8 (14) 15 (3.3) 4.9 (1.91‑12.58) 0.001a
D, Heavy drinkers
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 58 (100) 219 (100)
Pro/Proc 41 (70.7) 136 (62.1)
Pro/Ala 14 (24.1) 73 (33.3) 0.78 (0.39‑1.57) 0.48
Ala/Ala 3 (5.2) 10 (4.6) 0.97 (0.24‑3.94) 0.96
Pro/Ala+Ala/Ala 17 (29.3) 83 (37.9) 0.81 (0.42‑1.56) 0.52
Pro/Pro+Pro/Alac 55 (94.8) 209 (95.4)
Ala/Ala 3 (5.2) 10 (4.6) 1.04 (0.26‑4.19) 0.96
aP<0.01. bAdjusted for sex, age, smoking, and alcohol consumption. cUsed as reference. CRC, colorectal cancer.
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Atlas is a powerful public database integrating various omics 
data on human proteins in cells, tissues and organs, and can 
predict the association of level of particular protein interested 
with survival of patients with wide spectrum of cancer. Data 
analysis on the immunohistochemical study of the NINEIN 
proteins in CRC patients showed that patients with upregulated 
expression (as determined by the intensity of expression) strongly 
were associated with a poor prognosis (P=0.035, n=597).
Table VI. Association between NINEIN genotype and location of CRC in males.
A, Right colon cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 24 (100) 675 (100)
Pro/Proc 14 (58.3) 422 (62.5)
Pro/Ala 7 (29.2) 228 (33.8) 0.97 (0.38‑2.47) 0.95
Ala/Ala 3 (12.5) 25 (3.7) 3.6 (0.95‑13.73) 0.06
Pro/Ala+Ala/Ala 10 (41.7) 253 (37.5) 1.25 (0.54‑2.88) 0.6
Pro/Pro+Pro/Alac 21 (87.5) 650 (96.3)
Ala/Ala 3 (12.5) 25 (3.7) 3.64 (0.99‑13.37) 0.052
B, Left colon cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 89 (100) 675 (100)
Pro/Proc 58 (65.2) 422 (62.5)
Pro/Ala 23 (25.8) 228 (33.8) 0.84 (0.49‑1.41) 0.5
Ala/Ala 8 (9) 25 (3.7) 2.29 (0.94‑5.57) 0.07
Pro/Ala+Ala/Ala 31 (34.8) 253 (37.5) 1 (0.62‑1.61) 0.99
Pro/Pro+Pro/Alac 81 (91) 650 (96.3)
Ala/Ala 8 (9) 25 (3.7) 2.42 (1.01 5.82) 0.049
C, Colon cancer (other than rectal cancer)
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 52 (100) 675 (100)
Pro/Proc 37 (71.2) 422 (62.5)
Pro/Ala 11 (21.2) 228 (33.8) 0.63 (0.31‑1.28) 0.2
Ala/Ala 4 (7.7) 25 (3.7) 1.8 (0.57‑5.71) 0.32
Pro/Ala+Ala/Ala 15 (28.8) 253 (37.5) 0.76 (0.40‑1.44) 0.4
Pro/Pro+Pro/Alac 48 (92.3) 650 (96.3)
Ala/Ala 4 (7.7) 25 (3.7) 2.05 (0.65‑6.43) 0.22
D, Rectal cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORb (95% CI) P‑value
Total 61 (100) 675 (100)
Pro/Proc 35 (57.4) 422 (62.5)
Pro/Ala 19 (31.1) 228 (33.8) 1.15 (0.63‑2.08) 0.66
Ala/Ala 7 (11.5) 25 (3.7) 3.3 (1.26‑8.61) 0.01a
Pro/Ala+Ala/Ala 26 (42.6) 253 (37.5) 1.39 (0.80‑2.40) 0.24
Pro/Pro+Pro/Alac 54 (88.5) 650 (96.3)
Ala/Ala 7 (11.5) 25 (3.7) 3.15 (1.24‑8.02) 0.02a
aP<0.01. bAdjusted for sex, age, smoking, and alcohol consumption. cUsed as reference. CRC, colorectal cancer.
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Table VII. Association between NINEIN genotype and combination of smoking, alcohol consumption and location of CRC in 
males.
A, Right colon cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
Heavy smoker
  Total 11 (100) 339 (100)
  Pro/Prod 5 (45.4) 215 (63.4)
  Pro/Ala 4 (36.4) 111 (32.7) 1.78 (0.46‑6.96) 0.41
  Ala/Ala 2 (18.2) 13 (3.8) 6.94 (1.18‑40.82) 0.03a
  Pro/Ala+Ala/Ala 6 (54.5) 124 (36.6) 2.39 (0.69‑8.21) 0.17
  Pro/Pro+Pro/Alad 9 (81.8) 326 (96.2)
  Ala/Ala 2 (2) 13 (3.8) 5.57 (1.06‑29.44) 0.04a
Never/light drinkers
  Total 15 (100) 456 (100)
  Pro/Prod 7 (46.7) 286 (62.7)
  Pro/Ala 5 (33.3) 155 (34) 1.43 (0.44‑4.65) 0.55
  Ala/Ala 3 (20) 15 (3.3) 9.51 (2.13‑42.49) 0.003b
  Pro/Ala+Ala/Ala 8 (53.3) 170 (37.3) 2.1 (0.74‑5.97) 0.17
  Pro/Pro+Pro/Alad 12 (80) 441 (96.7)
  Ala/Ala 3 (20) 15 (3.3) 8.28 (2.02‑33.91) 0.003b
B, Left colon cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
Never/light drinkers
  Total 42 (100) 456 (100)
  Pro/Prod 26 (61.9) 286 (62.7)
  Pro/Ala 11 (26.2) 155 (34) 0.83 (0.40‑1.74) 0.62
  Ala/Ala 5 (11.9) 15 (3.3) 3.73 (1.21‑11.52) 0.02a
  Pro/Ala+Ala/Ala 16 (38.1) 170 (37.3) 1.09 (0.5‑2.12) 0.79
  Pro/Pro+Pro/Alad 37 (88.1) 441 (96.7)
  Ala/Ala 5 (11.9) 15 (3.3) 3.97 (1.31‑11.96) 0.01a
C, Colon cancer (other than rectal cancer)
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
Never/light drinkers
  Total 25 (100) 456 (100)
  Pro/Prod 16 (64) 286 (62.7)
  Pro/Ala 6 (24) 155 (34) 0.74 (0.28‑1.94) 0.54
  Ala/Ala 3 (12) 15 (3.3) 3.92 (0.999‑15.38) 0.0501
  Pro/Ala+Ala/Ala 9 (36) 170 (37.3) 1.01 (0.43‑2.36) 0.98
  Pro/Pro+Pro/Alad 22 (88) 441 (96.7)
  Ala/Ala 3 (12) 15 (3.3) 4.31 (1.13‑16.46) 0.03a
D, Rectal cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
Heavy smoker
  Total 17 (100) 336 (100)
  Pro/Prod 6 (35.3) 207 (61.6)
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Discussion
In the present case‑controlled study, the association between 
the NINEIN gene codon 1111 polymorphism and CRC risk in 
Japanese individuals was examined. NINEIN rs2236316 is a 
nonsynonymous single nucleotide polymorphism causing an 
amino acid substitution of Proline to Alanine at codon 1111. 
It was shown that the NINEIN Pro1111Ala variant was asso‑
ciated with the occurrence of CRC in Japanese individuals, 
particularly in males and in tumors of the left colon. To the 
best of our knowledge, this is the first report demonstrating 
that a NINEIN rs2236316 polymorphism is associated with 
the risk of CRC. There are two studies from the Mayo Clinic 
reporting polymorphisms in the NINEIN gene associated with 
pancreatic cancer and breast cancer in Caucasian popula‑
tions, focusing on mitosis regulation or centrosome structure 
and function pathways, respectively. In the pancreatic cancer 
study, NINEIN rs10145182 in intron2 had a significant OR with 
a reduced risk, particularly in the never‑smoker group (26). 
In contrast, in the breast cancer study, six single nucleotide 
polymorphisms of the NINEIN gene were identified, four of 
which were associated with an increased risk, and two of 
which were associated with a decreased risk of breast cancer, 
including rs10145182 (21). The rs2236316 polymorphism was 
not included in the breast cancer study.
Cigarette smoking and alcohol consumption have been 
suggested to influence the risk of CRC development in 
epidemiological studies (2‑6). In a pooled meta‑analysis 
based on cohort and case‑control studies, smoking was not 
shown to significantly increase the risk of CRC in Japanese 
individuals (2), whereas, alcohol consumption was reported to 
have a more significant positive association with the risk of CRC 
in the Japanese than those in Western populations (7). In the 
present study, ORs were notably higher for the Ala/Ala genotype 
overall among the never/light drinkers in males, in both the 
stratified tumor locations (left and right), and in patients with 
rectal cancer. Considering there was no increased risk among 
heavy drinkers, it may be interpreted that NINEIN functions in 
a pathway independent of alcohol‑associated oncogenesis.
The location of the tumor in patients with CRC has 
important clinical implications for the choice of therapy, as 
the left colon and the right colon have different embryonic 
origins, and they have different physiological and molecular 
backgrounds (8). Genomic instability of two major molecular 
mechanisms are respectively associated with CRC of the left 
and right colon; CIN is associated with tumors of the left 
colon and is a stage‑independent poor prognostic factor, and 
MIN is primarily associated with tumors of the right colon 
and infrequent metastasis (9,10). The Ala/Ala genotype was 
associated with an increased risk of CRC among patients 
with cancer of the left colon and rectal cancer in the strati‑
fied analysis of male patients with CRC. It has been estimated 
that chromosome instability in cancer cells is caused by 
aberrant expression and/or dysfunction of ~70 genes involved 
in centrosome function and chromosome segregation, or 
dysregulation of their associated signaling pathways (11). 
Cyclin B1 and cyclin B2 serve essential roles in the fidelity of 
centrosome separation and chromosome segregation in G2 to 
M phase progression of the cell cycle, and are overexpressed 
in several types of human tumors, including CRC. Whereas 
elevated expression of cyclin B1 prevents a cohesion cleavage 
and sister chromatid segregation resulting in the generation 
of aneuploid cells, overexpression of cyclin B2 is involved 
in the centrosome pathway and initiates activation of Plk1 
in an Aurora‑A‑dependent manner, resulting in a premature 
centrosome separation, spindle geometry defects and lagging 
Table VII. Continued.
D, Rectal cancer
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
  Pro/Ala 8 (47.1) 117 (34.8) 2.28 (0.77‑6.77) 0.14
  Ala/Ala 3 (17.6) 12 (3.6) 8.83 (1.92‑40.56) 0.01a
  Pro/Ala+Ala/Ala 11 (64.7) 129 (38.4) 2.86 (1.03‑7.96) 0.04a
  Pro/Pro+Pro/Alad 14 (82.4) 324 (96.4)
  Ala/Ala 3 (17.6) 12 (3.6) 6.01 (1.48‑24.33) 0.01a
Genotype CRC patients, n (%) Controls, n (%) Adjusted ORc (95% CI) P‑value
Never/light drinkers
  Total 30 (100) 456 (100)
  Pro/Prod 15 (50) 286 (62.7)
  Pro/Ala 10 (33.3) 155 (34) 1.4 (0.6‑3.26) 0.44
  Ala/Ala 5 (16.7) 15 (3.3) 7.06 (2.08‑24.03) 0.002b
  Pro/Ala+Ala/Ala 15 (50) 170 (37.3) 1.9 (0.88‑4.09) 0.1
  Pro/Pro+Pro/Alad 25 (83.3) 441 (96.7)
  Ala/Ala 5 (16.7) 15 (3.3) 6.23 (1.93‑20.11) 0.002b
aP<0.05, bP<0.01. cAdjusted for sex, age, smoking, and alcohol consumption. dUsed as reference. CRC, colorectal cancer.
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chromosomes during mitosis (11). It may be worthwhile inves‑
tigate whether NINEIN rs2236316 is associated with disease 
prognosis in patients with upregulated expression of NINEIN 
protein.
NINEIN localizes at a specific domain of the centrosome 
where it is essential for the recruitment of proteins associated 
with maturation of the daughter centrosome as well as for the 
reformation of specific aspects of the interphase centrosome 
architecture following mitosis (12). The NINEIN codon 1111 
polymorphism is located within a large coiled‑coil domain 
which is predicted to mediate the interaction with other 
centrosomal proteins (20). For instance, centrosomal protein 
CEP170 interacts with the domain containing amino acids 
802‑1,505 in NINEIN (27). Considering the importance of a 
cis‑trans isomer of the proline residue in the protein structure, 
a proline to alanine substitution at rs2236316 may impact the 
protein‑protein interaction of NINEIN, and as a result, centro‑
some structure and function and chromosome compression 
may be perturbed, resulting in genomic instability, a hallmark 
of cancer (28). Therefore, in the present study, the effect of an 
NINEIN P1111A substitution on centrosome localization and 
binding to CEP170 was assessed, but neither had any effect 
(data not shown). In future studies, the effects of amino acid 
substitutions in NINEIN by rs2236316 on centrosome function 
should be assessed to clarify the relationship with generation 
of CIN which is frequently observed in CRC.
The present case‑controlled study has several limitations 
including a small sample size, some self‑selection bias, such as 
volunteer bias, for the control group, and inadequate adjustment 
for various confounding factors, such as previous cancer treat‑
ment and drug disease‑state interactions. For stratified analyses, 
small sample sizes may limit the statistical significance of 
the present study. A more detailed stratification of the present 
cases with a combined association of sex, lifestyle habit and the 
primary area of CRC could not be performed due to the small 
number of female heavy smokers/heavy drinkers. Nonetheless, 
an association between an NINEIN polymorphism and 
increased‑risk groups of patients with CRC were determined.
In conclusion, it was shown that the variant allele 
Pro1111Ala of NINEIN was significantly associated with an 
increased risk of CRC among males, never/light drinkers and 
rectal cancer patients in males in Japan. Larger studies on the 
NINEIN polymorphisms are required to confirm the results of 
the present study, and the genotyping of NINEIN codon1111 
may eventually enable the identification of individuals at a high 
risk for the development of CRC, providing these individuals 
with an incentive to improve their lifestyle choices.
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